These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27724915)

  • 1. Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context.
    Moss R; McCaw JM; Cheng AC; Hurt AC; McVernon J
    BMC Infect Dis; 2016 Oct; 16(1):552. PubMed ID: 27724915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of neuraminidase inhibitors to combat pandemic influenza.
    Democratis J; Pareek M; Stephenson I
    J Antimicrob Chemother; 2006 Nov; 58(5):911-5. PubMed ID: 16956904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response.
    McVernon J; McCaw JM; Nolan TM
    Aust N Z J Public Health; 2010 Apr; 34(2):113-9. PubMed ID: 23331352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?
    Parra-Rojas C; Nguyen VK; Hernandez-Mejia G; Hernandez-Vargas EA
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30149615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
    Venkatesan S; Myles PR; Bolton KJ; Muthuri SG; Al Khuwaitir T; Anovadiya AP; Azziz-Baumgartner E; Bajjou T; Bassetti M; Beovic B; Bertisch B; Bonmarin I; Booy R; Borja-Aburto VH; Burgmann H; Cao B; Carratala J; Chinbayar T; Cilloniz C; Denholm JT; Dominguez SR; Duarte PAD; Dubnov-Raz G; Fanella S; Gao Z; Gérardin P; Giannella M; Gubbels S; Herberg J; Higuera Iglesias AL; Hoeger PH; Hu XY; Islam QT; Jiménez MF; Keijzers G; Khalili H; Kusznierz G; Kuzman I; Langenegger E; Lankarani KB; Leo YS; Libster RP; Linko R; Madanat F; Maltezos E; Mamun A; Manabe T; Metan G; Mickiene A; Mikić D; Mohn KGI; Oliva ME; Ozkan M; Parekh D; Paul M; Rath BA; Refaey S; Rodríguez AH; Sertogullarindan B; Skręt-Magierło J; Somer A; Talarek E; Tang JW; To K; Tran D; Uyeki TM; Vaudry W; Vidmar T; Zarogoulidis P; ; Nguyen-Van-Tam JS
    J Infect Dis; 2020 Jan; 221(3):356-366. PubMed ID: 31314899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.
    Beck CR; Sokal R; Arunachalam N; Puleston R; Cichowska A; Kessel A; Zambon M; Nguyen-Van-Tam JS;
    Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):14-24. PubMed ID: 23279893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis.
    Venkatesan S; Myles PR; Leonardi-Bee J; Muthuri SG; Al Masri M; Andrews N; Bantar C; Dubnov-Raz G; Gérardin P; Koay ESC; Loh TP; Memish Z; Miller E; Oliva ME; Rath BA; Schweiger B; Tang JW; Tran D; Vidmar T; Waight PA; Nguyen-Van-Tam JS
    Clin Infect Dis; 2017 May; 64(10):1328-1334. PubMed ID: 28199524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [French general practitioners' perceptions and use of neuraminidase inhibitors during the pandemic A(H1N1)2009 influenza].
    Barthe J; Noyelle C; Partouche H
    Sante Publique; 2011; 23(4):305-15. PubMed ID: 22177608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.
    Kawai N; Ikematsu H; Tanaka O; Matsuura S; Maeda T; Yamauchi S; Hirotsu N; Nishimura M; Iwaki N; Kashiwagi S
    J Infect Chemother; 2011 Jun; 17(3):375-81. PubMed ID: 21120678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15.
    Boikos C; Caya C; Doll MK; Kraicer-Melamed H; Dolph M; Delisle G; Winters N; Gore G; Quach C
    J Antimicrob Chemother; 2017 Jun; 72(6):1556-1573. PubMed ID: 28204554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects.
    Bijl D
    Int J Risk Saf Med; 2011; 23(2):65-71. PubMed ID: 21673413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.
    Venkatesan S; Carias C; Biggerstaff M; Campbell AP; Nguyen-Van-Tam JS; Kahn E; Myles PR; Meltzer MI
    J Public Health (Oxf); 2019 Jun; 41(2):379-390. PubMed ID: 29955851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase inhibitors and their role in avian and pandemic influenza.
    Crusat M; de Jong MD
    Antivir Ther; 2007; 12(4 Pt B):593-602. PubMed ID: 17944267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of influenza B virus infection and considerations for clinical management.
    Zaraket H; Hurt AC; Clinch B; Barr I; Lee N
    Antiviral Res; 2021 Jan; 185():104970. PubMed ID: 33159999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.
    Blanchon T; Geffrier F; Turbelin C; Daviaud I; Laouénan C; Duval X; Lambert B; Hanslik T; Mosnier A; Leport C
    Antivir Ther; 2015; 20(7):753-61. PubMed ID: 25687219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza antivirals and their role in pandemic preparedness.
    Jones JC; Yen HL; Adams P; Armstrong K; Govorkova EA
    Antiviral Res; 2023 Feb; 210():105499. PubMed ID: 36567025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Widespread use of neuraminidase inhibitors in Japan.
    Sugaya N
    J Infect Chemother; 2011 Oct; 17(5):595-601. PubMed ID: 21850418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and the Netherlands.
    Nuño M; Chowell G; Gumel AB
    J R Soc Interface; 2007 Jun; 4(14):505-21. PubMed ID: 17251132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.
    Chen L; Han X; Li YL; Zhang C; Xing X
    BMC Infect Dis; 2020 Aug; 20(1):628. PubMed ID: 32842994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.